MENU
LABU
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

LABU stock forecast, quote, news & analysis

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index")... Show more

Category: #Trading
LABU
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for LABU with price predictions
Sep 28, 2026

Momentum Indicator for LABU turns negative, indicating new downward trend

LABU saw its Momentum Indicator move below the 0 level on September 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In 93 of the 96 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for LABU turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 49 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

LABU moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for LABU crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LABU entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 64 cases where LABU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +9.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABU advanced for three days, in 296 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

LABU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index"). The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily S&P Biotech Bull 3X ETF (LABU) ETF is 13.62B. The market cap for tickers in the group ranges from 203.5M to 467.12B. ABBV holds the highest valuation in this group at 467.12B. The lowest valued company is CMPX at 203.5M.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF (LABU) ETF was 159%. For the same ETF, the average monthly price growth was 132%, and the average quarterly price growth was 306%. KOD experienced the highest price growth at 177%, while CMPX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF (LABU) ETF was -13%. For the same stocks of the ETF, the average monthly volume growth was 13% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 71
Price Growth Rating: 53
SMR Rating: 87
Profit Risk Rating: 80
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
LABU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Momentum Indicator for LABU turns negative, indicating new downward trend